Lung cancer
Conditions
Interventions
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria for all study participants: 1. Age 18 years or older. 2. Patients suspected of having lung malignancies who are attending multiple centers, including the lead institution, Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine, or healthy individuals participating in health examinations. 3. Willingness to participate in this study and signing of informed consent. If the participant is unable to read the consent form (e.g., an illiterate participant), the consent process must be witnessed, and the consent signed by a witness. Inclusion criteria for participants in the pathologically negative control and pathologically positive experimental cohorts: 1. Chest CT scan shows lung nodules or masses, with clinical suspicion of malignancy, requiring hospital admission for further diagnosis. 2. After admission, participants undergo bronchoscopy biopsy, CT-guided lung puncture biopsy, or surgery to obtain a pathological diagnosis and have complete clinical information (including age, gender, height, weight, smoking history, COPD history, family history of cancer, clinical or pathological TNM stage of lung cancer, and presence of lung infections and comorbidities). 3. Willingness to cooperate with hospital follow-up after discharge. Inclusion criteria for participants in the blank control cohort: 1. Health examination participants. 2. Chest CT scan shows no lung lesions, and there is no clinical basis for a diagnosis of lung malignancy. 3. Complete clinical information (including age, gender, height, weight, smoking history, COPD history, family history of cancer, and presence of lung infections and comorbidities). 4. Willingness to cooperate with hospital follow-up.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Concurrent severe systemic diseases (including severe ischemic cardiomyopathy, malignant arrhythmias, uncontrollable epilepsy, advanced COPD, severe lung infections, other malignancies, etc.). 2. Lack of biopsy-confirmed pathology results or incomplete clinical data (the blank control group is assumed to be pathologically negative). 3. Inability to cooperate with breath sampling, preventing the collection of valid breath fingerprint samples. 4. Vulnerable groups, including individuals with mental illnesses, cognitive impairments, critically ill patients, minors, and pregnant women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Breath fingerprint; | — |
Countries
China
Contacts
Public ContactZhengfu He
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Outcome results
None listed